In vitro activity of trospectomycin (U-63366F), a novel spectinomycin analog, against gram-positive isolates from cancer patients.
The in vitro activity of trospectomycin was compared to that of amikacin, cephalothin and vancomycin against gram-positive organisms, mostly isolated from cancer patients. Trospectomycin was considerably more active than amikacin against most isolates tested, particularly species of Staphylococcus and Streptococcus. Overall, vancomycin was the most active agent tested.